Altamira Therapeutics Ltd CYTOF
Trading Information
- Previous Close Price
- $0.09
- Day Range
- $0.08–0.08
- 52-Week Range
- $0.05–0.15
- Bid/Ask
- $0.05 / $0.10
- Shares Outstanding
- 5.72M
- Market Cap
- $484,900.64
- Volume/Avg
- 1,635 / 8,905
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
Valuation
|
Metric
|
CYTOF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.12 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CYTOF
Financial Strength
|
Metric
|
CYTOF
|
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.11 |
Interest Coverage | −110.72 |
Quick Ratio
CYTOF
Profitability
|
Metric
|
CYTOF
|
|---|---|
Return on Assets (Normalized) | −76.47% |
Return on Equity (Normalized) | −107.56% |
Return on Invested Capital (Normalized) | −97.63% |
Return on Assets
CYTOF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nR@Xh&< | LOCK|%S!d@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R!??fsG | LOCK|>hc# | $83B | |||
| Moderna Inc
MRNA
| LOCK|pm<h&R$ | LOCK|!< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|@@hGV@ | LOCK|zp | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|SW&%!k$ | LOCK|?VX | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^@?<%P& | LOCK|%Wkt? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pPWy!vy | LOCK|r#X@W | $28B | |||
| Incyte Corp
INCY
| LOCK|Q&Br?< | LOCK|H>c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%V?jDSh | LOCK|z& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^w^zv$ | LOCK|Fx | $14B |
United States